318 related articles for article (PubMed ID: 16227400)
1. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine.
Chuang JC; Yoo CB; Kwan JM; Li TW; Liang G; Yang AS; Jones PA
Mol Cancer Ther; 2005 Oct; 4(10):1515-20. PubMed ID: 16227400
[TBL] [Abstract][Full Text] [Related]
2. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy.
Segura-Pacheco B; Trejo-Becerril C; Perez-Cardenas E; Taja-Chayeb L; Mariscal I; Chavez A; Acuña C; Salazar AM; Lizano M; Dueñas-Gonzalez A
Clin Cancer Res; 2003 May; 9(5):1596-603. PubMed ID: 12738711
[TBL] [Abstract][Full Text] [Related]
3. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide.
Lin X; Asgari K; Putzi MJ; Gage WR; Yu X; Cornblatt BS; Kumar A; Piantadosi S; DeWeese TL; De Marzo AM; Nelson WG
Cancer Res; 2001 Dec; 61(24):8611-6. PubMed ID: 11751372
[TBL] [Abstract][Full Text] [Related]
4. GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells.
Chiam K; Centenera MM; Butler LM; Tilley WD; Bianco-Miotto T
PLoS One; 2011; 6(9):e25634. PubMed ID: 21980513
[TBL] [Abstract][Full Text] [Related]
5. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.
Christman JK
Oncogene; 2002 Aug; 21(35):5483-95. PubMed ID: 12154409
[TBL] [Abstract][Full Text] [Related]
6. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine.
Karpf AR; Moore BC; Ririe TO; Jones DA
Mol Pharmacol; 2001 Apr; 59(4):751-7. PubMed ID: 11259619
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Momparler RL; Côté S; Eliopoulos N
Leukemia; 1997 Mar; 11 Suppl 1():S1-6. PubMed ID: 9130684
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines.
Bender CM; Pao MM; Jones PA
Cancer Res; 1998 Jan; 58(1):95-101. PubMed ID: 9426064
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of dna methylation by 5-aza-2'-deoxycytidine correlates with induction of K562 cells differentiation.
Fabianowska-Majewska K; Wyczechowska D; Czyz M
Adv Exp Med Biol; 2000; 486():343-7. PubMed ID: 11783512
[No Abstract] [Full Text] [Related]
10. S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth.
Chuang JC; Warner SL; Vollmer D; Vankayalapati H; Redkar S; Bearss DJ; Qiu X; Yoo CB; Jones PA
Mol Cancer Ther; 2010 May; 9(5):1443-50. PubMed ID: 20442312
[TBL] [Abstract][Full Text] [Related]
11. [The study of 5-Aza-2'-deoxycytidine on transcription regulation of p16/CDKN2 gene demethylation in RKO human colorectal cell line].
Fang XM; Sun LF; Peng JP; Dong Q; Zheng S
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2077-82. PubMed ID: 14703421
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia.
Lemaire M; Momparler LF; Bernstein ML; Marquez VE; Momparler RL
Anticancer Drugs; 2005 Mar; 16(3):301-8. PubMed ID: 15711182
[TBL] [Abstract][Full Text] [Related]
13. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer.
Balch C; Yan P; Craft T; Young S; Skalnik DG; Huang TH; Nephew KP
Mol Cancer Ther; 2005 Oct; 4(10):1505-14. PubMed ID: 16227399
[TBL] [Abstract][Full Text] [Related]
14. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines.
Stresemann C; Brueckner B; Musch T; Stopper H; Lyko F
Cancer Res; 2006 Mar; 66(5):2794-800. PubMed ID: 16510601
[TBL] [Abstract][Full Text] [Related]
15. Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents.
Mirza S; Sharma G; Pandya P; Ralhan R
Mol Cell Biochem; 2010 Sep; 342(1-2):101-9. PubMed ID: 20455010
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Momparler RL; Côté S; Eliopoulos N
Leukemia; 1997 Feb; 11(2):175-80. PubMed ID: 9009076
[TBL] [Abstract][Full Text] [Related]
17. DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity.
Kim HJ; Kim JH; Chie EK; Young PD; Kim IA; Kim IH
Radiat Oncol; 2012 Mar; 7():39. PubMed ID: 22429326
[TBL] [Abstract][Full Text] [Related]
18. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
Flotho C; Claus R; Batz C; Schneider M; Sandrock I; Ihde S; Plass C; Niemeyer CM; Lübbert M
Leukemia; 2009 Jun; 23(6):1019-28. PubMed ID: 19194470
[TBL] [Abstract][Full Text] [Related]
19. NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer.
Liu M; Peng Y; Wang X; Guo Q; Shen S; Li G
BMC Cancer; 2010 Apr; 10():160. PubMed ID: 20423473
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells.
Primeau M; Gagnon J; Momparler RL
Int J Cancer; 2003 Jan; 103(2):177-84. PubMed ID: 12455031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
